"Pharmacogenetic testing enables us to tailor drug treatments to individual patients based on their unique genetic makeup, or genotype," says Dr. Shuldiner, an endocrinologist and geneticist. "With genotype-directed therapy, we have the ability to change the 'one size fits all' approach to prescribing medication and ultimately improve the quality of care we provide to our patients. Patients want personalized and individualized medicine. They seek it out."
The test is performed by analyzing the patient's DNA, isolated from a blood sample, in a new state-of-the-art translational genomics laboratory at the University of Maryland School of Medicine. The tests are being conducted as part of a National Institutes of Health (NIH)-funded study to determine the best way to implement genetic-testing programs. Tests are free, and because of the partnership between UMMC and the University of Maryland School of Medicine, results are available within a few hours.
Dr. Shuldiner explains that the ability to provide test results within hours is crucial because cardiac stent patients are at risk for developing blood clots and other complications soon after they have the procedure. "This rapid turnaround time sets our program apart from other programs and commercial laboratories, where results may not be available for up to two weeks," he adds.
Pharmacogenomics how genes affect a person's response to drugs is a burgeoning area of research, but only a small number of hospitals in the United States have programs to offer routine genetic testing as part of their clinical practice. This new approach to patient care is part of the University of Maryland School of Medicine's purs
|Contact: Karen Warmkessel|
University of Maryland Medical Center